Details of the Drug

General Information of Drug (ID: DMSQZE2)

Drug Name

Asenapine

Synonyms

Asenapi; Asenapine [INN:BAN]; Saphris (TN); [13C,2H3]-Asenipine; Trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-met; 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

285.8

Logarithm of the Partition Coefficient (xlogp)

3.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance: The drug present in the plasma can be removed from the body at the rate of 12.4 mL/min/kg [3]
Elimination: 1% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 24 hours [3]
Metabolism: The drug is metabolized via the CYP1A2 and undergoes direct glucuronidation via UGT1A4 []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.711 micromolar/kg/day [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.05% [3]
Vd: The volume of distribution (Vd) of drug is 20-25 L/kg []

Chemical Identifiers

Formula: C17H16ClNO
IUPAC Name: (2R,6R)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
Canonical SMILES: CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24
InChI: InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1
InChIKey: VSWBSWWIRNCQIJ-GJZGRUSLSA-N

Cross-matching ID

PubChem CID: 3036780
ChEBI ID: CHEBI:71246
CAS Number: 65576-45-6
DrugBank ID: DB06216
TTD ID: D00JRA
INTEDE ID: DR0146
ACDINA ID: D00045

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hyaluronidase (HYAL)	TTXFI1K	NOUNIPROTAC	Modulator	[5]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[7]
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Asenapine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Asenapine and Amisulpride.	Schizophrenia [6A20]	[8]
-----------

Coadministration of a Drug Treating the Disease Different from Asenapine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Asenapine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[9]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Midostaurin.	Acute myeloid leukaemia [2A60]	[10]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Arn-509.	Acute myeloid leukaemia [2A60]	[11]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[10]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Asenapine and Oliceridine.	Acute pain [MG31]	[12]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Asenapine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[13]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Asenapine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[13]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Asenapine and Ivabradine.	Angina pectoris [BA40]	[11]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Asenapine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[14]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Levalbuterol.	Asthma [CA23]	[15]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Asenapine caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[16]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Eribulin.	Breast cancer [2C60-2C6Y]	[10]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Asenapine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[17]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Bosutinib.	Breast cancer [2C60-2C6Y]	[10]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[10]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Asenapine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[15]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Asenapine and Pasireotide.	Cushing syndrome [5A70]	[10]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Osilodrostat.	Cushing syndrome [5A70]	[10]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Asenapine and OPC-34712.	Depression [6A70-6A7Z]	[19]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Asenapine and Esketamine.	Depression [6A70-6A7Z]	[20]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Asenapine and Deutetrabenazine.	Dystonic disorder [8A02]	[21]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Ingrezza.	Dystonic disorder [8A02]	[10]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Teriflunomide	DMQ2FKJ	Moderate	Increased metabolism of Asenapine caused by Teriflunomide mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[20]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Asenapine and Levamlodipine.	Hypertension [BA00-BA04]	[22]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Asenapine and TAK-491.	Hypertension [BA00-BA04]	[22]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Asenapine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[23]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Asenapine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[19]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Asenapine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[10]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Asenapine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[11]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Asenapine and Crizotinib.	Lung cancer [2C25]	[24]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Asenapine and Ceritinib.	Lung cancer [2C25]	[10]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Asenapine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[25]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Asenapine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[26]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Asenapine and Osimertinib.	Lung cancer [2C25]	[27]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Asenapine caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[23]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Asenapine and Selpercatinib.	Lung cancer [2C25]	[11]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Asenapine and Lumefantrine.	Malaria [1F40-1F45]	[20]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Asenapine and Vemurafenib.	Melanoma [2C30]	[10]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and LGX818.	Melanoma [2C30]	[10]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Asenapine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[28]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Asenapine and Lasmiditan.	Migraine [8A80]	[29]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Asenapine and Panobinostat.	Multiple myeloma [2A83]	[30]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Asenapine and Siponimod.	Multiple sclerosis [8A40]	[20]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Asenapine and Fingolimod.	Multiple sclerosis [8A40]	[10]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Asenapine and Ozanimod.	Multiple sclerosis [8A40]	[31]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Asenapine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[20]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Rucaparib.	Ovarian cancer [2C73]	[10]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Triclabendazole.	Parasitic worm infestation [1F90]	[10]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Asenapine when combined with Opicapone.	Parkinsonism [8A00]	[32]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Asenapine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[33]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Asenapine and Methylscopolamine.	Peptic ulcer [DA61]	[19]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Asenapine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[34]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Asenapine and Lefamulin.	Pneumonia [CA40]	[35]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Degarelix.	Prostate cancer [2C82]	[11]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Enzalutamide.	Prostate cancer [2C82]	[11]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Asenapine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[11]
LEE011	DMMX75K	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[10]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[11]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Pitolisant.	Somnolence [MG42]	[10]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[10]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Asenapine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[36]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Asenapine and Lenvatinib.	Thyroid cancer [2D10]	[10]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Asenapine and Cabozantinib.	Thyroid cancer [2D10]	[11]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Asenapine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[19]
-----------


⏷ Show the Full List of 67 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sucralose	E00370	71485	Flavoring agent
Gelatin	E00630	Not Available	Other agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Asenapine 10 mg tablet	10 mg	Sublingual Tablet	Oral
Asenapine 5 mg tablet	5 mg	Sublingual Tablet	Oral
Asenapine Maleate eq 2.5mg base tablet	eq 2.5mg base	Tablet	Sublingual
Asenapine Maleate eq 5mg base tablet	eq 5mg base	Tablet	Sublingual
Asenapine Maleate eq 10mg base tablet	eq 10mg base	Tablet	Sublingual

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 22).
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504.
7	Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903.
8	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
9	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
10	Canadian Pharmacists Association.
11	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
13	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
14	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
15	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
16	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
17	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
18	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
19	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
20	Cerner Multum, Inc. "Australian Product Information.".
21	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
22	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
23	Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
24	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
25	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
26	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
28	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
29	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
30	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
31	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
32	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
33	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
34	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
35	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
36	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.